Bharat Biotech Company
UWMadison, FLuGen and Bharat said April 2 they had begun development and testing of CoroFlu, based on FluGen’s M2SR, a self-limiting version of the influenza virus that induces an immune response against the flu. M2SR was based on an invention by UWMadison virologists and FluGen co-founders Yoshihiro Kawaoka, PhD, and Gabriele Neumann, PhD, with Kawaoka’s lab planning to insert gene sequences from SARS-CoV-2 into M2SR so that the new vaccine will also induce immunity against the coronavirus.
The partners said they expect to refine the CoroFlu vaccine concept and carry out tests in animal models at UW–Madison over the next three to six months. Bharat Biotech of Hyderabad, India, will then begin production scale-up for safety and efficacy testing in humans. CoroFlu could be in human clinical trials by the fall of 2020, the partners added.
The partners said they expect to refine the CoroFlu vaccine concept and carry out tests in animal models at UW–Madison over the next three to six months. Bharat Biotech of Hyderabad, India, will then begin production scale-up for safety and efficacy testing in humans. CoroFlu could be in human clinical trials by the fall of 2020, the partners added.
Technology:
COVID
Industry:
Vaccine/Drug
Headquarters:
India
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership